Niagen Bioscience Inc
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
NAGE$2.28+10.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed orFurnishedHerewith | ||||||
|---|---|---|---|---|---|---|
| Exhibit No. · Description · Form · File Number · Exhibit · Filing Date | ||||||
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 10-K | 001-37752 | 3.1 | 3/15/2018 | |
| 3.2 | Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation | 8-K | 000-53290 | 3.1 | 3/19/2025 | |
| 3.3 | Amended and Restated Bylaws of Niagen Bioscience, Inc. | 8-K | 000-53290 | 3.1 | 3/19/2025 | |
| 4.1 | Form of Stock Certificate representing shares of the Registrant’s Common Stock | X | ||||
| 10.1 | Amendment to Amended and Restated Executive Employment Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant | 8-K | 001-37752 | 10.1 | 2/27/2025 | |
| 10.2 | Performance Stock Unit Award Agreement, dated February 25, 2025, by and between Robert Fried and the Registrant | 8-K | 001-37752 | 10.2 | 2/27/2025 | |
| 10.3 | Second Amendment to Lease Agreement, dated March 11, 2025, by and between ChromaDex Analytics, Inc. and 62 1625-1751 S. Fordham LLC and 64 1625-1751 S. Fordham LLC | X | ||||
| 10.4 | Seventh Modification to Business Financing Agreement dated March 24, 2025 by and among Western Alliance Bank, Niagen Bioscience, Inc., ChromaDex Inc. and ChromaDex Analytics, Inc. | X | ||||
| 10.5 | Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended | X | ||||
| 10.6 | Form of Stock Option Agreement under Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended | X | ||||
| 10.7 | Form of Restricted Stock Purchase Agreement under the Niagen Bioscience, Inc. 2017 Equity Incentive Plan, as amended | X | ||||
| 10.8 | Amended and Restated Non-Employee Director Compensation Policy | X | ||||
| 10.9 | Amended and Restated Incentive Compensation Recoupment Policy | X | ||||
| 31.1 | Certification of the Chief Executive Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended | X | ||||
| 31.2 | Certification of the Chief Financial Officer pursuant to Rule 13a-14(A) of the Securities Exchange Act of 1934, as amended | X | ||||
| 32.1 | Certification pursuant to 18 U.S.C. Section 1350 (as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002) | X | ||||
| 101.INS | Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||
| 104 | 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.